Inventiva (IVA) Common Equity (2018 - 2025)
Inventiva (IVA) posted quarterly Common Equity of -$33.2 million for Q4 2025, up 70.87% year-over-year from -$19.4 million in Q4 2024, and up 99.67% quarter-over-quarter from -$10.1 billion in Q2 2025.
Analysis
Inventiva (IVA) Common Equity (2018 - 2025) Analysis & Trends
Inventiva's Common Equity history runs 8 years deep, the most recent figure standing at -$33.2 million for Q4 2025.
- In Q4 2025, Common Equity rose 70.87% year-over-year to -$33.2 million; the TTM figure through Dec 2025 stood at -$33.2 million (up 70.87% YoY), while the FY2025 annual figure was -$33.2 million, up 70.87% from the prior year.
- Common Equity for Q4 2025 stood at -$33.2 million, up from -$10.1 billion in the prior quarter.
- The five-year high for Common Equity was $74.4 billion in Q2 2022, with the low at -$10.1 billion in Q2 2025.
- The 5-year median for Common Equity is $8.1 million (2023), against an average of $5.4 billion.
- The sharpest annual moves came in 2022 and 2025: Common Equity surged 69694.74% in 2022, then plunged 11744.94% in 2025.
- Inventiva's Common Equity stood at $101.7 million in 2021, then plunged by 54.36% to $46.4 million in 2022, then sank by 174.28% to -$34.5 million in 2023, then tumbled by 230.67% to -$114.0 million in 2024, then soared by 70.87% to -$33.2 million in 2025.
- Business Quant data shows IVA's Common Equity at -$33.2 million in Q4 2025, -$10.1 billion in Q2 2025, and -$114.0 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 8.42 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 6.76 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.61 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.17 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.79 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Inventiva | 893.85 Mn | 893.85 Mn | - | -33.20 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -33.20 Bn |
| Jun 30, 2025 | -10.08 Mn |
| Dec 31, 2024 | -113.96 Mn |
| Jun 30, 2024 | -85.14 Mn |
| Dec 31, 2023 | -34.46 Mn |
| Jun 30, 2023 | -8.35 Mn |
| Dec 31, 2022 | 46.40 Mn |
| Jun 30, 2022 | 74.40 Mn |
| Dec 31, 2021 | 101.66 Mn |
| Jun 30, 2021 | 106.60 Mn |
| Mar 31, 2021 | 123.34 Mn |
| Dec 31, 2020 | 132.60 Mn |
| Jun 30, 2020 | 45.97 Mn |
| Dec 31, 2019 | 45.82 Mn |
| Dec 31, 2018 | 70.31 Mn |